Update
OpenAI Buys Orchestra Bio to Integrate AI into Drug Development
OpenAI has acquired Orchestra Bio, a San Francisco startup that uses AI agents to streamline drug development processes. OpenAI plans to integrate Orchestra’s AI agents into Rosalind, its suite of AI models and tools for biologists and chemists. This move aims to reduce the time and cost associated with bringing a new medicine to market, which can take up to 15 years and cost over $2.6 billion. Orchestra’s AI agents help coordinate work across internal departments and external partners, reducing the need for manual oversight and improving efficiency.